B. Riley Securities Reiterates Buy Rating for Kymera Therapeutics
B. Riley Securities maintains a bullish stance on Kymera Therapeutics with a $155 price target, a 35.17% upside from the current price.
Key Points
- B. Riley Securities reiterated its buy rating for Kymera Therapeutics on June 29, 2026, with a price target of $155.
- B. Riley Securities's $155 price target implies 35.17% upside from Kymera Therapeutics, Inc.'s ($KYMR) current $114.67 share price.
- Shares of Kymera Therapeutics traded near $108.12 on Monday, with a market cap of $8.89 billion and a beta of 2.03.
- Institutional investors like FMR LLC and T. Rowe Price Investment Management have adjusted their holdings in Kymera.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B. Riley Securities has reiterated its buy rating for Kymera Therapeutics, Inc. (NASDAQ:KYMR) on June 29, 2026. The firm set a price target of $155, maintaining its bullish outlook on the biotechnology company. Shares of Kymera Therapeutics traded near $108.12 on Monday.
B. Riley Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Kymera Therapeutics
Several institutional investors have recently adjusted their positions in Kymera Therapeutics. FMR LLC increased its holdings by 2,771,376 shares, ending with 11,699,950 shares valued at about $974.49 million, marking a 31% increase. T. Rowe Price Investment Management added 4,835,252 shares, boosting its stake by 767.8% to a total of 5,464,997 shares worth approximately $455.18 million. Meanwhile, Price T Rowe Associates slightly reduced its position by 98,488 shares, now holding 6,060,847 shares valued at $504.81 million.
Kymera Therapeutics, Inc. Stock Down 2.9%
Shares of Kymera Therapeutics traded close to $108.12 on Monday. The company boasts a market capitalization of approximately $8.89 billion and has a beta of 2.03, indicating higher volatility compared to the market. The stock's 52-week range is between $36.65 and $130.05. Its 50-day moving average is $84.71, while the 200-day moving average is $75.08. Kymera maintains a strong financial position with a current ratio of 10.81 and a quick ratio of 10.39, alongside a debt-to-equity ratio of 5.23.
$KYMR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Kymera Therapeutics reported revenue of $51.48 million, reflecting a growth rate of 55.5%. Despite this, the company has no meaningful P/E ratio as it is not currently profitable, with an EPS of -$3.58 and a return on equity of -27.1%. The next earnings report is expected on August 10, 2026.
Insider Buying and Selling at Kymera Therapeutics, Inc.
Recent insider activity includes BVF Partners P/IL selling 1,630,658 shares on June 26, 2026, at an average price of $106.50. On June 25, 2026, Bruce Booth sold 548,321 shares at an average price of $118.76 under a pre-planned 10b5-1 trading plan. Noah Goodman, the Chief Business Officer, sold 5,000 shares at $114.00, also on June 25, under a similar plan.
Analysts Set New Price Targets
On June 29, 2026, B. Riley Securities maintained its buy rating for Kymera Therapeutics with a $155 price target. Truist Securities also maintained a buy rating with a target of $136 on the same day. Canaccord Genuity reaffirmed its buy rating on June 26, 2026, setting a price target of $129. Overall, the consensus among 21 analysts is a strong buy, with a mean price target of $123.05.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a biotechnology company based in Watertown, Massachusetts. It focuses on developing small molecule therapeutics that harness the body's natural protein degradation processes to selectively degrade disease-causing proteins. The company is advancing several candidates, including KT-621 for atopic dermatitis and KT-579 for autoimmune diseases. Kymera collaborates with Sanofi S.A. to develop drug candidates targeting IRAK4 outside the oncology field.
Bottom Line
B. Riley Securities' reiterated buy rating for Kymera Therapeutics underscores the firm's confidence in the company's growth potential. As a clinical-stage biopharmaceutical company, Kymera's focus on innovative therapeutics makes it a watchlist candidate for investors. Keep in mind that these analyst ratings are backward-looking and may not reflect the company's current business dynamics.
Get Kymera Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $KYMR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.